A Prospective Study to Assess the Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC) Patients With Weight Loss
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Men, Women, and all genders
• Individuals 18 years old or older are included.
• Patients of the study investigators and team members
• Diagnosis of pancreatic ductal adenocarcinoma
• All subjects must consent to this study
• Clinically diagnosed weight loss
Locations
United States
California
Cedars-Sinai Medical Center
RECRUITING
Los Angeles
Contact Information
Primary
Abrahm Levi
abrahm.levi@cshs.org
310-248-8084
Time Frame
Start Date: 2025-04-14
Estimated Completion Date: 2026-04-14
Participants
Target number of participants: 100
Treatments
Pancreatic adenocarcinoma with clinically significant weight loss.
Patients diagnosed with pancreatic adenocarcinoma with clinically significant weight loss.
Related Therapeutic Areas
Sponsors
Leads: Cedars-Sinai Medical Center